Drug Trial Radar · NCT01762514
A Phase II Clinical Trial on Comparison of Effectiveness and Safeness of Different Amifostine Regimens
Last checked: Nov 20, 2026Latest source record: Jul 13, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
360
Planned (sponsor's estimate)
Start
Jan 2013
Primary completion
Jun 2019
Study completion Dec 2019
Sponsor
- Lead sponsor
- Sun Yat-sen UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Dalian Merro Pharmaceutical Co. Ltd
- First posted
- Jan 7, 2013
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RATIONALE * Radiotherapy is the primary therapeutic strategy for nasopharyngeal carcinoma. * Radiotherapy may cause adverse effect such as xerostomia and mucositis. * Amifostine has the ability of protecting the normal tissue but also has some side effects. PURPOSE * This phase II trial is to study the protecting effect and safety of different Amifostine regimens in patients with nasopharyngeal carcinoma.
Conditions
- Nasopharyngeal Neoplasms
- Salivary Gland Diseases
- Bone Marrow Diseases
- Mucositis
Interventions
Amifostine every-other-day regimenDrug
Amifostine 400mg/d, every-other-day regimen from Monday to Friday, every week repetition during radiotherapy
Amifostine everyday regimenDrug
Amifostine 400mg/d, everyday regimen from Monday to Friday, every week repetition during radiotherapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Effect on improving myelosuppressionTime frame: One week before radiotherapy; Once a week during radiotherapy, up to 7 weeks; Three months after radiotherapy
- Effect on improving xerostomiaTime frame: One week before radiotherapy; Once a week during radiotherapy, up to 7 weeks; Three months after radiotherapy
- Effect on improving mucositisTime frame: One week before radiotherapy; Once a week during radiotherapy, up to 7 weeks; Three months after radiotherapy
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
The Main Guangzhou Hospital of the Guangzhou Military Region
Guangzhou, Guangdong, China · Suspended
Department of Radiation Oncology, Sun Yat-Sen University Cancer Center
Guangzhou, Guangdong, China · Recruiting
The Affiliated Cancer Hospital Of Guangzhou Medical Collage
Guangzhou, Guangdong, China · Suspended
Guangdong Provincial Hospital Of Chinese Medicine
Guangzhou, Guangdong, China · Suspended
The First Affiliated Hospital Of Guangzhou Medical Collage
Guangzhou, Guangdong, China · Recruiting
The Second Affiliated Hospital, Sun Yat-Sen University
Guangzhou, Guangdong, China · Suspended
Guangdong Second People's Hospital
Guangzhou, Guangdong, China · Withdrawn
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.